Sumeet Munjal, MD
Nephrology · Montgomery, ALNPI 1578819546
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,768 of the $191,002 with a category attached, or 71.6%. 25 manufacturers reported payments, led by AstraZeneca at 39.0% of the total. 2025 is the largest year on record at $60,762, more than ten times the $1,081 reported in 2019. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 650 payments — averaging $293.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$75K
- Otsuka America Pharmaceutical, Inc.$44K
- GSK$22K
- Bayer$22K
- Akebia Therapeutics Inc$21K
- Vifor Pharma, Inc.$3K
- plus $5K from 19 others
What the payments were for
- Consulting fees$20,88411%
- Speaking & faculty fees$136,76872%
- Travel & lodging$18,57110%
- Food & beverage$14,5868%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 150 | $74,550 |
| Otsuka America Pharmaceutical, Inc. | 106 | $44,036 |
| GSK | 34 | $22,108 |
| Bayer | 67 | $21,556 |
| Akebia Therapeutics Inc | 65 | $20,597 |
| Vifor Pharma, Inc. | 19 | $3,399 |
| Vantive US Healthcare LLC | 9 | $1,500 |
| OPKO Pharmaceuticals, LLC | 83 | $751 |
| Amgen(2 entities) | 37 | $692 |
| Fresenius USA Marketing, Inc. | 25 | $522 |
| Calliditas Therapeutics US Inc. | 14 | $298 |
| Lilly USA, LLC | 7 | $136 |
| Novartis | 4 | $125 |
| Travere Therapeutics, Inc. | 6 | $123 |
| Aurinia Pharma U.S., Inc. | 5 | $115 |
| Mallinckrodt Enterprises LLC | 2 | $115 |
| Boehringer Ingelheim | 5 | $111 |
| Baxter Healthcare | 2 | $64 |
| Ardelyx, Inc. | 2 | $58 |
| Lundbeck LLC | 3 | $52 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,002 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 332 | $300,868 |
| JynarqueTolvaptan | 14 | $268,173 |
| KerendiaFinerenone | 75 | $80,827 |
| JardianceEmpagliflozin | 62 | $58,280 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $39,052 |
| AuryxiaFerric Citrate | 24 | $34,568 |
| VelphoroSucroferric Oxyhydroxide | 11 | $28,128 |
| Sevelamer Carbonate | 104 | $15,364 |
| RayaldeeCalcifediol | 13 | $14,913 |
| Calcitriol | 69 | $2,410 |
| Nifedipine ErNifedipine | 73 | $2,342 |
| Hydralazine Hcl | 63 | $2,314 |
| Calcium Acetate | 22 | $2,036 |
| Olmesartan Medoxomil | 43 | $1,795 |
| Midodrine Hcl | 24 | $1,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $74,550 | $339,920380 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $44,036 | $268,17314 claims |
| BayerKerendia | $21,556 | $80,82775 claims |
| Boehringer IngelheimJardiance | $111 | $58,28062 claims |
| Akebia Therapeutics IncAuryxia | $20,597 | $34,56824 claims |
| Fresenius USA Marketing, Inc.Velphoro | $522 | $28,12811 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $751 | $14,91313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 nephrology providers in Alabama.
Other nephrology in Montgomery
- Rafael LopezMontgomery$6K
- Kim McGlothanMontgomery$5K
- Melanie HalvorsonMontgomery$4K
- Rodney SmithMontgomery$4K
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.